Abstract
Supplementation of dietary fiber has been proved to be an effective strategy to prevent and relieve inflammatory bowel disease (IBD) through gut microbiota modulation. However, more attention has been paid to the efficacy of soluble dietary fiber than that of insoluble dietary fiber (IDF). In the present study, we investigated whether IDF from barley leaf (BLIDF) can inhibit gut inflammation via modulating the intestinal microbiota in DSS-induced colitis mice. The mice were fed 1.52% BLIDF-supplemented diet for 28 days. Results demonstrated that feeding BLIDF markedly mitigated DSS-induced acute colitis symptoms and down-regulated IL-6, TNF-α, and IL-1β levels in the colon and serum of colitis mice. BLIDF supplementation effectively reduced the abundance of Akkermansia and increased the abundance of Parasutterella, Erysipelatoclostridium, and Alistipes. Importantly, the anti-colitis effects of BLIDF were abolished when the intestinal microbiota was depleted by antibiotics. Furthermore, the targeted microbiota-derived metabolites analysis suggested that BLIDF feeding can reverse the DSS-induced decline of short-chain fatty acids and secondary bile acids in mice feces. Finally, BLIDF supplementation elevated the expression of occludin and mucin2, and decreased the expression of claudin-1 in colons of DSS-treated mice. Overall, our observations suggest that BLIDF exerts anti-inflammatory effects via modulating the intestinal microbiota composition and increasing the production of microbiota-derived metabolites.
Highlights
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic recurrent intestinal immune-mediated disease characterized by dysregulated immune responses and gut microbiota [1,2]
Our work suggested that dietary supplementation of barley leaf insoluble dietary fiber (BLIDF) prominently ameliorated dextran sodium sulfate (DSS)-induced gut microbiota dysbiosis, which may result in the increased production of microbiota-derived metabolites, restoration of impaired gut barrier function, and remission of colitis
A significant body weight loss, elevated Disease Activity Index (DAI) score, The protective effects of BLIDF against colitis were evaluated in DSS-induced acute and colon length shortening were observed in the CT+DSS group (Figure 1B–E)
Summary
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic recurrent intestinal immune-mediated disease characterized by dysregulated immune responses and gut microbiota [1,2]. The intestinal microbiota in IBD hosts is characterized by a decline in microbial diversity and altered bacterial composition, including a reduced abundance of Clostridia, Lachnospiraceae, and Alistipes, and an elevated abundance of Enterobacteriaceae species [4,5]. Oral transfer of the fecal microbiota from IBD patients into microbiota-depleted IL-10−/− mice promoted colitis development [7]. These results indicate that the intestinal microbiota is a crucial factor in colonic inflammation development
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
